Home > Research > Publications & Outputs > The politics of EU health policy and the case o...

Research

Associated organisational units

Links

Text available via DOI:

Keywords

View graph of relations

The politics of EU health policy and the case of direct-to-consumer advertising for prescription drugs

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

The politics of EU health policy and the case of direct-to-consumer advertising for prescription drugs. / Geyer, Robert.
In: The British Journal of Politics and International Relations, Vol. 13, No. 4, 11.2011, p. 586-602.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Geyer, R 2011, 'The politics of EU health policy and the case of direct-to-consumer advertising for prescription drugs', The British Journal of Politics and International Relations, vol. 13, no. 4, pp. 586-602. https://doi.org/10.1111/j.1467-856X.2011.00460.x

APA

Geyer, R. (2011). The politics of EU health policy and the case of direct-to-consumer advertising for prescription drugs. The British Journal of Politics and International Relations, 13(4), 586-602. https://doi.org/10.1111/j.1467-856X.2011.00460.x

Vancouver

Geyer R. The politics of EU health policy and the case of direct-to-consumer advertising for prescription drugs. The British Journal of Politics and International Relations. 2011 Nov;13(4):586-602. doi: 10.1111/j.1467-856X.2011.00460.x

Author

Geyer, Robert. / The politics of EU health policy and the case of direct-to-consumer advertising for prescription drugs. In: The British Journal of Politics and International Relations. 2011 ; Vol. 13, No. 4. pp. 586-602.

Bibtex

@article{f69e1df8f33b411ab093dd42d87ca577,
title = "The politics of EU health policy and the case of direct-to-consumer advertising for prescription drugs",
abstract = "Direct-to-consumer advertising for prescription drugs (DTCA-PD) is currently banned in the EU, but the pharmaceutical industry (supported by key member states and DG Enterprise) made two major attempts to overturn it in the 2000s at the EU level and failed. What does this failure imply for the debates surrounding this policy area and EU health policy in general? To explore this question, this article will define DTCA-PD, examine its pros and cons, provide a brief overview of EU health policy and present a detailed review of the two recent attempts to overturn the ban. Following this, it will examine the five key elements of EU health policy, evaluate their relevance to the development of the EU's policy towards DTCA-PD and briefly speculate on the future of the ban.",
keywords = "European Union, health policy, direct to consumer advertising, prescription drugs, patient information, EU theory",
author = "Robert Geyer",
year = "2011",
month = nov,
doi = "10.1111/j.1467-856X.2011.00460.x",
language = "English",
volume = "13",
pages = "586--602",
journal = "The British Journal of Politics and International Relations",
issn = "1467-856X",
publisher = "SAGE PUBLICATIONS INC",
number = "4",

}

RIS

TY - JOUR

T1 - The politics of EU health policy and the case of direct-to-consumer advertising for prescription drugs

AU - Geyer, Robert

PY - 2011/11

Y1 - 2011/11

N2 - Direct-to-consumer advertising for prescription drugs (DTCA-PD) is currently banned in the EU, but the pharmaceutical industry (supported by key member states and DG Enterprise) made two major attempts to overturn it in the 2000s at the EU level and failed. What does this failure imply for the debates surrounding this policy area and EU health policy in general? To explore this question, this article will define DTCA-PD, examine its pros and cons, provide a brief overview of EU health policy and present a detailed review of the two recent attempts to overturn the ban. Following this, it will examine the five key elements of EU health policy, evaluate their relevance to the development of the EU's policy towards DTCA-PD and briefly speculate on the future of the ban.

AB - Direct-to-consumer advertising for prescription drugs (DTCA-PD) is currently banned in the EU, but the pharmaceutical industry (supported by key member states and DG Enterprise) made two major attempts to overturn it in the 2000s at the EU level and failed. What does this failure imply for the debates surrounding this policy area and EU health policy in general? To explore this question, this article will define DTCA-PD, examine its pros and cons, provide a brief overview of EU health policy and present a detailed review of the two recent attempts to overturn the ban. Following this, it will examine the five key elements of EU health policy, evaluate their relevance to the development of the EU's policy towards DTCA-PD and briefly speculate on the future of the ban.

KW - European Union

KW - health policy

KW - direct to consumer advertising

KW - prescription drugs

KW - patient information

KW - EU theory

U2 - 10.1111/j.1467-856X.2011.00460.x

DO - 10.1111/j.1467-856X.2011.00460.x

M3 - Journal article

VL - 13

SP - 586

EP - 602

JO - The British Journal of Politics and International Relations

JF - The British Journal of Politics and International Relations

SN - 1467-856X

IS - 4

ER -